» Articles » PMID: 26999212

Proteomics Analysis Reveals Novel RASSF2 Interaction Partners

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2016 Mar 22
PMID 26999212
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

RASSF2 is a tumor suppressor that shares homology with other Ras-association domain (RASSF) family members. It is a powerful pro-apoptotic K-Ras effector that is frequently inactivated in many human tumors. The exact mechanism by which RASSF2 functions is not clearly defined, but it likely acts as a scaffolding protein, modulating the activity of other pro-apoptotic effectors, thereby regulating and integrating tumor suppressor pathways. However, only a limited number of RASSF2 interacting partners have been identified to date. We used a proteomics based approach to identify additional RASSF2 interactions, and thereby gain a better insight into the mechanism of action of RASSF2. We identified several proteins, including C1QBP, Vimentin, Protein phosphatase 1G and Ribonuclease inhibitor that function in diverse biological processes, including protein post-translational modifications, epithelial-mesenchymal transition, cell migration and redox homeostasis, which have not previously been reported to interact with RASSF2. We independently validated two of these novel interactions, C1QBP and Vimentin and found that the interaction with C1QBP was enhanced by K-Ras whereas, interestingly, the Vimentin interaction was reduced by K-Ras. Additionally, RASSF2/K-Ras regulated the acetylation of Vimentin. Our data thus reveal novel mechanisms by which RASSF2 may exert its functions, several of which may be Ras-regulated.

Citing Articles

Tumor suppressor C-RASSF proteins.

Iwasa H, Hossain S, Hata Y Cell Mol Life Sci. 2018; 75(10):1773-1787.

PMID: 29353317 PMC: 11105443. DOI: 10.1007/s00018-018-2756-5.


KRAS Activation and over-expression of SIRT1/BCL6 Contributes to the Pathogenesis of Endometriosis and Progesterone Resistance.

Yoo J, Kim T, Fazleabas A, Palomino W, Ahn S, Tayade C Sci Rep. 2017; 7(1):6765.

PMID: 28754906 PMC: 5533722. DOI: 10.1038/s41598-017-04577-w.


The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence.

Barnoud T, Schmidt M, Donninger H, Clark G Cancer Lett. 2017; 400:30-36.

PMID: 28455242 PMC: 5502528. DOI: 10.1016/j.canlet.2017.04.030.


Ras signaling through RASSF proteins.

Donninger H, Schmidt M, Mezzanotte J, Barnoud T, Clark G Semin Cell Dev Biol. 2016; 58:86-95.

PMID: 27288568 PMC: 5034565. DOI: 10.1016/j.semcdb.2016.06.007.

References
1.
Song H, Oh S, Oh H, Lim D . Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity. Biochem Biophys Res Commun. 2009; 391(1):969-73. DOI: 10.1016/j.bbrc.2009.11.175. View

2.
van der Weyden L, Adams D . The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta. 2007; 1776(1):58-85. PMC: 2586335. DOI: 10.1016/j.bbcan.2007.06.003. View

3.
Donninger H, Vos M, Clark G . The RASSF1A tumor suppressor. J Cell Sci. 2007; 120(Pt 18):3163-72. DOI: 10.1242/jcs.010389. View

4.
Gharanei S, Brini A, Vaiyapuri S, Alholle A, Dallol A, Arrigoni E . RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma. Epigenetics. 2013; 8(9):893-8. PMC: 3883766. DOI: 10.4161/epi.25617. View

5.
Serrano M, Lin A, McCurrach M, Beach D, Lowe S . Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88(5):593-602. DOI: 10.1016/s0092-8674(00)81902-9. View